ReviewAdvanced drug delivery reviews2021
Self-assembled mRNA vaccines.
Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
236 citing papers in PubMed, 481 citations in OpenAlex.
- An mRNA-Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-ResistantbioRxiv : the preprint server for biology · 2026Article
- Molecular mastery: Harnessing DNA technology for disease prevention.Genes & diseases · 2026Review
- Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy.Bioactive materials · 2026Article
- Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery.Small methods · 2026Article
- Advances in FRET-based Applications Within Biomimicking Molecular Self-assemblies.Journal of fluorescence · 2026Review
- Plant-Based Oral Vaccines: Molecular Biotechnology Approaches Toward Functional Food-Based Immunization.Molecular biotechnology · 2026Review
- Analytical Characterization and Stability Assessment of RNA-Based Vaccines.Pharmaceutics · 2026Review
- Using an RNA binding protein to detect mRNA on lipid nanoparticles.Scientific reports · 2026Article
- Understanding Size Distributions during Lipid Nanoparticle Manufacturing through Mechanistic Modeling.ACS omega · 2026Article
- Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines.Cancer cell international · 2026Review
- mRNA vaccines for viral diseases: mechanism, advances, and future perspective.Molecular biology reports · 2026Review
- mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules.Discover oncology · 2026Review
- Article
- Article
- Transformer-based multidimensional feature fusion for accurate prediction of lipid nanoparticles transfection efficiency.Briefings in bioinformatics · 2026Article
- Potent and Long-Lasting Immunogenicity Generated by LNP-mRNA gE Antigen Against Varicella Zoster Virus via an AI-Assisted Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lipid-Polymer Nanoparticles (LiPoNs) Mediated Codelivery of AntimiR-21 and Gadolinium Chelate in Triple Negative Breast Cancer Theranostics.Bioengineering (Basel, Switzerland) · 2026Article
- A novel mRNA nanovaccine with dual immunoregulation ameliorates rheumatoid arthritis and associated pneumonia.Asian journal of pharmaceutical sciences · 2026Article
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
- Direct Cytoplasmic Transcription and Trimeric RBD Design Synergize to Enhance DNA Vaccine Potency Against SARS-CoV-2.Pharmaceutics · 2026Article
176 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology, and nanotechnology have generated interest in delivering safe and effective mRNA therapeutics. In this review, we discuss design and self-assembly of mRNA vaccines. Self-assembly, a spontaneous organization of individual molecules, allows for design of nanoparticles with customizable properties. We highlight the materials commonly utilized to deliver mRNA, their physicochemical characteristics, and other relevant considerations, such as mRNA optimization, routes of administration, cellular fate, and immune activation, that are important for successful mRNA vaccination. We also examine the COVID-19 mRNA vaccines currently in clinical trials. mRNA vaccines are ready for the clinic, showing tremendous promise in the COVID-19 vaccine race, and have pushed the boundaries of gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.